Q1 EPS Estimates for Haemonetics Lifted by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Equities research analysts at Zacks Research raised their Q1 2028 EPS estimates for Haemonetics in a research note issued on Wednesday, January 28th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings of $1.39 per share for the quarter, up from their previous forecast of $1.38. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share.

Other equities analysts have also issued reports about the stock. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. JPMorgan Chase & Co. raised their price target on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a report on Friday, December 12th. BTIG Research reissued a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a report on Friday, January 9th. Citigroup cut their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 price target on shares of Haemonetics in a research report on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $84.40.

Haemonetics Trading Up 0.9%

Shares of Haemonetics stock opened at $66.54 on Friday. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The company has a market capitalization of $3.11 billion, a P/E ratio of 19.46, a P/E/G ratio of 1.37 and a beta of 0.29. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. The company has a fifty day moving average of $78.47 and a 200 day moving average of $65.44.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The firm had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.

Institutional Investors Weigh In On Haemonetics

Several hedge funds have recently bought and sold shares of the stock. True Wealth Design LLC increased its holdings in shares of Haemonetics by 6,700.0% during the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 335 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares during the period. GAMMA Investing LLC increased its holdings in Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 165 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 567 shares during the period. Finally, Bayforest Capital Ltd purchased a new stake in shares of Haemonetics during the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.